Biopsy materials from these patients should be immunohistochemically tested for estrogen receptor, progesterone receptor, and HER2 before treatment, both to support a diagnosis of breast cancer and to plan treatment strategies for these patients. This evidence concerns the gene ERBB2 and breast carcinoma.